CASI Pharmaceuticals (CASI) Insider Trading & Ownership $2.38 +0.10 (+4.39%) As of 11:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CASI Pharmaceuticals (NASDAQ:CASI) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage21.24%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$1.02 MNumber OfInsiders Selling(Last 3 Years)0 Get CASI Insider Trade Alerts Want to know when executives and insiders are buying or selling CASI Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CASI Insider Buying and Selling by Quarter CASI Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/8/2022James HuangDirectorBuy33,300$4.28$142,524.00 9/6/2022James HuangDirectorBuy19,162$3.89$74,540.18 8/26/2022James HuangDirectorBuy39,527$3.75$148,226.25 8/24/2022James HuangDirectorBuy5,000$3.75$18,750.00 8/22/2022James HuangDirectorBuy23,105$3.46$79,943.30 8/19/2022James HuangDirectorBuy171,116$3.27$559,549.32 (Data available from 1/1/2013 forward) CASI Insider Trading Activity - Frequently Asked Questions Who is on CASI Pharmaceuticals's Insider Roster? The list of insiders at CASI Pharmaceuticals includes James Huang. Learn more on insiders at CASI. What percentage of CASI Pharmaceuticals stock is owned by insiders? 21.24% of CASI Pharmaceuticals stock is owned by insiders. Learn more on CASI's insider holdings. CASI Pharmaceuticals Key ExecutivesDr. Wei-Wu He Ph.D. (Age 59)Chairman & CEO Compensation: $565.36kDr. Wei Zhang Ph.D. (Age 64)President Compensation: $1.13MDr. Alexander A. Zukiwski M.D. (Age 67)Executive VP & Chief Medical Officer Compensation: $514.79kMs. Kun Qian (Age 42)VP & Global Controller Ms. Chunhua Wang (Age 52)Chief Operating Officer Ms. Wei Gao (Age 43)General Counsel Dr. James E. Goldschmidt Ph.D.Chief Business Development OfficerMr. Hai Huang (Age 55)Global Chief Commercial Officer Ms. Amanda CuiVP & Global Controller More Insider Trading Tools from MarketBeat Related Companies ACRS Insider Ownership ALEC Insider Ownership FTLF Insider Ownership ZNTL Insider Ownership ADAP Insider Ownership TSVT Insider Ownership MCRB Insider Ownership ACTU Insider Ownership GNLX Insider Ownership CKPT Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 2 Stocks Insiders Are Buying and 1 They're Selling3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q4 This page (NASDAQ:CASI) was last updated on 3/6/2025 by MarketBeat.com Staff From Our PartnersA crypto nightmareThis past weekend President Trump made good his promise to crypto enthusiasts - with his announcement of an of...Stansberry Research | SponsoredAlert: DOGE goes liveElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredIgnore Fox Business’s “man who calls it all” at your perilThis is the biggest AI investment story you’ve never been told… and people who invest before March 19 could st...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CASI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
